Skip to main
FULC
FULC logo

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics Inc is positioned for significant revenue growth, with projected revenues reaching approximately $560 million by 2028, driven by robust opportunities in the sickle cell disease market due to limited current treatment options. Recent clinical data indicate promising efficacy for losmapimod and FTX-6058, with notable increases in fetal hemoglobin levels and a substantial proportion of patients achieving clinically relevant thresholds, reducing the incidence of vaso-occlusive crises. Additionally, the company's enterprise value has increased to $1.39 billion, reflecting investor confidence and the potential financial impact of its ongoing clinical programs.

Bears say

Fulcrum Therapeutics Inc faces significant challenges that could adversely impact its stock performance, primarily due to concerns regarding intellectual property protection and competitive positioning. The potential for negative developmental outcomes related to its lead candidate, pociredir, as well as the possibility of failing to achieve regulatory approval, raises substantial risks for the company's future market potential and revenue projections. Furthermore, the lower baseline hemoglobin levels observed in Cohort 4 participants suggest that the efficacy of pociredir may be diminished, complicating the company’s prospects for meeting critical clinical endpoints.

FULC has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Buy based on their latest research and market trends.

According to 7 analysts, FULC has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.